The Centers for Medicare and Medicaid Services is not reconsidering the national coverage determination for Food and Drug Administration (FDA)-approved medications for Alzheimer’s disease.

The FDA-approved monoclonal antibodies are directed against amyloid, or the protein buildup, for the treatment of Alzheimer’s disease.